Published in Women's Health Weekly, April 28th, 2005
The application will now be assessed under the centralized approval procedure, which, following an approval, grants the applicant the right to market the product in all EU markets.
"We believe that the data submitted demonstrate the safety and efficacy of Preotact and support the approval of the product for treatment of osteoporosis in postmenopausal women. With a positive assessment from EMEA, Preotact could be ready...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly